WeVote
Log In

Bill

Bill

LR 219

Interim study to examine nonopioid pharmacological treatment options in medicaid

109th Legislature (2025-2026) Introduced by John Fredrickson

Nebraska LR 219 directs an interim study by the Health and Human Services Committee to evaluate nonopioid pharmacological options in Medicaid, aiming to expand access and reduce op

Referred to Health and Human Services Committee
0
WeVote Research Nonpartisan
Bill Summary · LR 219

Summary of Nebraska Legislative Resolution LR 219 (2025)

Executive Summary

LR 219 is a proposed interim study resolution in the Nebraska Legislature. Introduced on May 15, 2025, and sponsored by Senator Fredrickson (primary), the resolution directs an interim study by the Health and Human Services Committee to examine nonopioid pharmacological treatment options within Nebraska’s Medicaid program. The goal is to identify opportunities, barriers, and initiatives related to nonopioid pain management, assess the benefits and risks of opioid use, and explore potential Medicaid cost savings from reducing opioid addiction and deaths.

Purpose and Intent

  • Propose an interim study to evaluate nonopioid pharmacological treatment options in Medicaid.
  • Assess opportunities and barriers to accessing nonopioid pharmacological treatments within Medicaid programs.
  • Evaluate initiatives to promote nonopioid pain management within Medicaid.
  • Evaluate the benefits and risks associated with opioid use.
  • Investigate potential cost savings in Medicaid that could result from increasing the use of nonopioid pharmacological options due to reductions in opioid addiction and mortality.

Key Provisions

  • Designation of the Health and Human Services Committee to conduct the interim study and carry out the purposes of the resolution.
  • Upon completion, the committee must prepare and submit a report detailing findings and recommendations to the Legislative Council (or Legislature).

Scope and Coverage

  • Topic: Medicaid program in Nebraska, focusing on nonopioid pharmacological treatment options and pain management.
  • Considerations include access barriers, program initiatives to promote nonopioid therapies, opioid-related risks, and potential cost savings tied to reducing opioid misuse, addiction, and deaths.

Process and Timeline

  • Interim study to be conducted by the designated committee (Health and Human Services Committee).
  • Final report of findings and recommendations to be presented to the Legislative Council or Legislature after the study concludes.
  • Specific deadlines or end dates are not stated in the bill; as an interim resolution, work typically occurs during the legislative interim period.

Affected Parties

  • Medicaid beneficiaries in Nebraska.
  • Nebraska Medicaid program administrators and policymakers.
  • Healthcare providers, insurers, and stakeholders involved in pain management and prescribing practices.
  • Public health and patient safety organizations.

Procedural Notes

  • Classification: Legislative Resolution (not a bill creating law or appropriations).
  • Status: Referred to Executive Board (May 15, 2025) and to the Health and Human Services Committee (May 19, 2025).
  • Sponsor: Senator Fredrickson (primary).

Potential Impacts

  • Informed policy decisions on expanding nonopioid pharmacological options within Medicaid.
  • Identification of barriers to access and development of initiatives to promote nonopioid pain management.
  • Evidence-based assessment of the benefits/risks of opioid use within Medicaid.
  • Possible recommendations for cost-saving strategies tied to reducing opioid-related harms.

This summary provides a concise, nonpartisan overview of LR 219 and its potential implications for Medicaid policy and pain management in Nebraska.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.